Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ECTRIMS 2022 | Natalizumab: a strategy for immunization to avoid delays of treatment onset in highly active MS

The use of high-efficacy immunosuppressive drugs for the treatment of multiple sclerosis (MS) raises concerns about the increased risk of infections. One strategy to address the increased infection risk is to vaccinate patients. However, vaccination during immunosuppression can result in impaired vaccine responses. In highly active patients requiring a rapid treatment initiation, vaccination can delay treatment onset. Mar Tintoré, MD, PhD, Vall d’Hebron University Hospital, Barcelona, Spain, and President of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), discusses the possibility of using natalizumab, a high-efficacy agent with potential low interference in vaccination responses, as a bridge therapy to achieve an adequate immunization before starting another treatment. In highly active patients who need immunization, this could be a valuable strategy to avoid delays in the onset of high-efficacy treatment. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress 2022 in Amsterdam, The Netherlands.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


M Tintore has received compensation for:
Consulting services and speaking honoraria from Almirall, Bayer Schering Pharma, Biogen-Idec, Genzyme, Janssen, Merck-Serono, Novartis, Roche, Sanofi-Aventis, Viela Bio, Viatris and Teva Pharmaceuticals.
Receipt grants and research supports from Carlos III Health Institute, Foundation Genzyme, Foundation Salud 2000, Biogen-Idec, Novartis.